Project Grant R01AG081192

Award Date 6/15/24
Completion Date 3/31/29
Dollars Obligated $3.8M
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $444,890 to The Regents of the University of California, San Francisco (UCSF) to explore the mechanisms driving the selective vulnerability of brain regions to distinct pathological conformers of the Alzheimer's disease (AD) and Lewy body dementia (LBD)-related proteins, tau and alpha-synuclein. The research will utilize mathematical modeling and in vivo mouse studies to identify candidate genes...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $452,550 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to investigate the role of reactive astrogliosis, specifically the upregulation of the glial fibrillary acidic protein (GFAP), in Alzheimer's disease-related synaptic dysfunction and loss. The project aims to determine whether and how GFAP upregulation in reactive astrocytes impacts the protein...
This $1.8 million project grant from the National Institutes of Health's National Institute of Mental Health will fund the development of high-throughput methods for measuring synaptic connectivity at single-cell resolution in the cerebral cortex. Over a three-year period from September 2022 through August 2025, The Broad Institute, Inc. will pursue viral, functional, and molecular approaches to map local cortical circuitry. These include optimizing rabies-based trans-synaptic tracing for...
This Project Grant award from the National Institute on Aging (NIA) under CFDA 93.866 Aging Research will fund a $3,929,011 longitudinal, multimodal neuroimaging study to elucidate the role of neuronal dysfunction and hyperexcitability in the early biological progression of Alzheimer's disease. The study will be conducted by the University of California, San Francisco (UCSF) and aims to identify the earliest manifestations of neural circuit hyperexcitability that predict the accumulation of...
This $4.49 million project grant from the National Institutes of Health's National Institute on Aging will fund research at The Washington University to investigate the relationship between amyloid plaque deposition, cellular metabolic dysfunction, and functional brain organization in Alzheimer's disease (AD) mice models. Over three years, the researchers will use multi-photon fluorescence lifetime imaging microscopy, multi-parametric photoacoustic microscopy, and wide-field optical imaging to...
The National Institute on Aging (NIA) awarded a $4,276,054 Project Grant under the Aging Research program (CFDA 93.866) to The Regents of the University of California, San Francisco (UCSF) to conduct mathematical modeling and analysis of selective vulnerability in mouse tauopathy models relevant to Alzheimer's disease (AD). The project aims to quantitatively test hypotheses related to how protein aggregation, neural cell type composition, and network-based transmission of pathology contribute to...
The University of California, Irvine was awarded a $773,816 Project Grant from the National Institute on Aging (CFDA 93.866 - Aging Research) to conduct cell-type-specific and spatial proteogenomics analysis of aberrant RNA splicing and misfolded proteins in Alzheimer's-related tauopathies. The research aims to generate single-cell spatial proteo-transcriptomics maps to molecularly characterize aberrant RNA splicing and abnormal protein products in specific brain cell types in mouse models and...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) totaling $2,840,883 will fund a proteomic comparison of sporadic early-onset, late-onset, and autosomal dominant Alzheimer's disease (AD) at Emory University. The goal is to advance the understanding of sporadic early-onset AD pathophysiology and how it compares to late-onset and autosomal dominant forms of the disease. The project will leverage a multi-platform discovery proteomic approach to analyze...
This $459,076 federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) aims to identify early transcriptional and pathological changes in vulnerable brain regions during the prodromal stage of Alzheimer's disease (AD). The primary awardee, Trustees of Boston University, will perform single-nucleus RNA sequencing and targeted mass spectrometry analyses on postmortem brain samples from individuals with early-stage AD pathology. This will yield a...
The National Institute on Aging (NIA) awarded a $429,000 Project Grant (CFDA 93.866 - Aging Research) to Northeast Ohio Medical University (Neomed) to evaluate the role of acetylation on brain proteome dynamics in a mouse model of Alzheimer's Disease (AD) and type 2 diabetes mellitus (T2DM). The 2-year project aims to quantify proteome and acetylome dynamics in the hippocampus and frontal cortex of diet-induced diabetic and non-diabetic AD mice to determine the effect of T2DM-related...

INCORPORATING SPATIAL PROTEOMICS TO UNDERSTAND THE BASIS OF HYPER AND HYPOCONNECTIVITY IN MOUSE MODELS OF AD - IN THIS PROPOSAL, WE PROPOSE STUDIES TO ELUCIDATE THE BASIS OF THE HYPER AND HYPOCONNECTIVITY OBSERVED IN AD. WE WILL COMBINE HIGH RESOLUTION IN VIVO MRI IMAGING STRATEGIES WITH STATE-OF THE-ART SPATIAL PROTEOMICS. BY COMBINING THESE METHODS, WE WILL OBTAIN THESE TWO TYPES OF DATA IN THE SAME ANIMAL, ALLOWING US TO INCORPORATE MACHINE LEARNING (ML) TO BUILD A MODEL TO DEFINE SPATIALLY DISTINCT PROTEIN EXPRESSION CHANGES IN REGIONS OF HYPER AND HYPOCONNECTIVITY OVER TIME. A RECENT MRI/PET IMAGING STUDY SUGGESTED THAT TAU TANGLES ARE RESPONSIBLE FOR HYPOCONNECTIVITY, WHILE AB PLAQUES ARE RESPONSIBLE FOR HYPERCONNECTIVITY. THIS INTRIGUING HYPOTHESIS, BASED ON DATA FROM A HETEROGENEOUS GROUP OF PATIENTS, NEEDS TO BE TESTED UNDER CAREFULLY CONTROLLED CONDITIONS THAT CAN ONLY BE OBTAINED USING ANIMAL MODELS OF AD. PET IMAGING IDENTIFIES TAU TANGLES AND AB PLAQUES BUT CANNOT DETERMINE WHICH PHOSPHORYLATED TAU (P-TAU) SPECIES ARE DRIVING HYPOCONNECTIVITY, NOR CAN IT DETERMINE THE CONTRIBUTION OF SOLUBLE AB42 TO THE HYPERCONNECTIVITY. IN THE STUDIES PROPOSED IN THIS APPLICATION, WE WILL TEST THREE HYPOTHESES: 1) SOLUBLE AB42 ACCUMULATION CAUSES REGIONS OF HYPERCONNECTIVITY. 2) A SUBSET OF SOLUBLE P-TAU SPECIES IS RESPONSIBLE FOR HYPOCONNECTIVITY. 3) REGIONS OF HYPER AND HYPOCONNECTIVITY EXHIBIT DISTINCT SPATIAL PROTEOMIC PROFILES THAT REFLECT EARLY AND LATE PHASES OF THE DISEASE.

Posted 6/14/24, 12:00 AM